Form 4: CRINX Insider Transactions: Director/CEO Shifts Holdings

Richard Scott Struthers, Director and President & CEO of Crinetics Pharmaceuticals, Inc., reported significant changes in beneficial ownership of common stock on May 29, 2026.

Summary

• Richard Scott Struthers, who holds the positions of Director and President & CEO at Crinetics Pharmaceuticals, Inc., has reported a series of transactions affecting his beneficial ownership of the company's common stock.
• These transactions, all occurring on May 29, 2026, involve both dispositions (D) and acquisitions (A) of common stock, with various trusts and his spouse listed as recipients or sources of these shares.
• The filing details the transfer of shares to and from the Struthers Family Trust, the Struthers Family Charitable Remainder Trust, GMS Dynasty Trust, JSS Dynasty Trust, Iowa Descendants Trust, and RSS Dynasty Trust, as well as direct transfers to his spouse.
• Following these reported transactions, Struthers' beneficial ownership is detailed across direct and indirect holdings, with specific amounts attributed to different trusts and his spouse.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it primarily reports on routine insider transactions related to stock ownership adjustments and trust management, without indicating significant positive or negative corporate events.

Positives

• The reporting person, Richard Scott Struthers, is actively involved in managing his beneficial ownership, indicating engagement with the company's stock.
• The transactions include contributions to charitable trusts, demonstrating corporate social responsibility.

Negatives

• The filing primarily details dispositions of stock, which could be interpreted as a reduction in direct holdings by a key executive, although these are often part of estate planning or trust management.
• The complexity of the transactions across multiple trusts and indirect ownership could obscure the true net change in beneficial ownership for an external observer.

Risks

• While not explicitly stated as risks, the frequent transfers to various trusts could indicate a strategy to diversify holdings or prepare for future liquidity needs, which might be a concern for some investors if not part of a pre-defined plan.
• The disclaimer of beneficial ownership for certain trusts, except to the extent of pecuniary interest, adds a layer of complexity in assessing direct control over all listed shares.

Future Outlook

This filing does not contain forward-looking statements or guidance. It solely reports on past transactions.

Management Comments

• The reporting person disclaims beneficial ownership of shares held by the Charitable Trust, Family Trust 5, Family Trust 6, Family Trust 7, and Family Trust 8, except to the extent of his pecuniary interest therein.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for significant shareholders and company insiders, providing transparency into stock ownership changes. The complexity of trusts involved in this filing is not uncommon for executives managing substantial holdings.

Related Party Transactions

• Transactions involving the Struthers Family Trust, Struthers Family Charitable Remainder Trust, the reporting person's spouse, GMS Dynasty Trust, JSS Dynasty Trust, Iowa Descendants Trust, and RSS Dynasty Trust.

Stakeholder Impact

• Shareholders: The filing provides transparency on insider holdings, which can influence investor confidence. The nature of the transactions (gifts, contributions to trusts) suggests estate planning or wealth management rather than a sale driven by negative outlook.
• Management: Confirms the ongoing role and stock management activities of the President & CEO and Director.
• Beneficiaries of Trusts: The transactions directly impact the assets held within the various family and charitable trusts.

Next Steps

• Continued monitoring of Richard Scott Struthers' beneficial ownership and any future transactions.
• Analysis of the company's overall financial health and strategic direction, which would be found in other SEC filings (e.g., 10-K, 10-Q).

Key Dates

Keywords

Form 4, SEC Filing, Insider Trading, Beneficial Ownership, Stock Transactions, Crinetics Pharmaceuticals, Richard Scott Struthers, Director, CEO, Common Stock, Trusts